These and other SMAD3/PITX1 downstream targets also present different expression levels in high-grade glioma (HGG) and low-grade glioma (LGG) tissue samples from the human protein atlas (Supplementary Fig. 11). This evidence concerns the gene SMAD3 and central nervous system cancer.